Does Nivolumab Cause Skin Pigmentation Changes?
Yes, skin pigmentation changes, including hyperpigmentation (darkening) and hypopigmentation (lightening), are reported side effects of nivolumab (Opdivo), a PD-1 inhibitor used for cancers like melanoma and lung cancer. These occur due to immune-related adverse events affecting melanocytes, often appearing as vitiligo-like depigmentation or patchy discoloration.[1][2]
How Common Are These Skin Changes?
Pigmentation alterations affect 10-20% of patients on nivolumab, more frequently in melanoma cases (up to 25% for vitiligo-like changes). They typically emerge 2-6 months after starting treatment and can persist or worsen with continued use.[1][3]
What Do Skin Changes Look Like with Nivolumab?
Patients describe poliosis (white hair), depigmented patches on face/hands, or generalized hyperpigmentation. These are immune-mediated, distinct from chemotherapy-induced changes, and often signal treatment response in melanoma.[2][4]
Are These Changes Reversible?
Many cases stabilize or partially reverse after stopping nivolumab, but some permanent vitiligo-like effects occur in 5-10% of patients. Topical steroids or calcineurin inhibitors help manage symptoms.[1][3]
How Does This Compare to Ipilimumab or Pembrolizumab?
Nivolumab alone causes less severe skin effects than ipilimumab combo (30-40% incidence), but similar to pembrolizumab. Combination therapy increases risk significantly.[2][4]
What Should Patients Do If They Notice Pigmentation Changes?
Report to oncologist promptly; it may require dermatology consult or dose adjustment. Not all changes need stopping therapy, as they can correlate with better outcomes.[1][3]
[1]: Opdivo (nivolumab) Prescribing Information, BMS
[2]: PubMed: Dermatologic adverse events with anti-PD-1 therapy
[3]: NEJM: Immune-related cutaneous toxicity with nivolumab
[4]: JAMA Dermatology: Vitiligo in PD-1 inhibitor therapy